SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease

Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to reduce cardiovascular risk and mortality in patients with type 2 diabetes mellitus (T2D), yet remain underutilized in clinical practice. This study aimed...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ziad Arow, Tzipi Hornik-Lurie, Ranin Hilu, Ela Giladi, Yoav Arnson, Hana Vaknin-Assa, Abid Assali, David Pereg, For the CARDIAB research group
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-08-01
coleção:	Cardiovascular Diabetology
Assuntos:	Type 2 diabetes mellitus Atherosclerotic cardiovascular disease Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) Glucagon-like peptide-1 receptor agonists (GLP-1RA)
Acesso em linha:	https://doi.org/10.1186/s12933-025-02874-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!